Ryufin

Sartorius Stedim Biotech S.A.

France · FR0013154002 · reports in EUR · Europe

The answers

From the annual report for the year to Dec 31, 2025. Each line says what it is based on.

Is it growing?Fair
Revenue +6.7% in the year to Dec 31, 2025, on the year before.
Is it a good business?Fair
It earned 6.5% on its shareholders' equity in the year to Dec 31, 2025.
Is it safe?Good
Equity is 52% of its assets, and operations brought in cash in the year.
Is the price fair?n/a
Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.

The year

Year to Dec 31, 2025, consolidated, in EUR.

€3.0B

revenue

18%

operating margin

€266M

net profit

Year by year

As filed; an earlier year can differ from its own report when the company restated it.

Dec 2022Dec 2023Dec 2024Dec 2025
Revenue€3.5B€2.8B€2.8B€3.0B
Operating profit€995M€449M€371M€526M
Net profit to shareholders€876M€310M€175M€266M
Earnings per share€9.51€3.36€1.81€2.73
Dividend per sharen/a€1.44n/a€0.69
Cash from operations€612M€746M€815M€692M
Cash€107M€117M€679M€426M
Total assets€5.1B€7.7B€8.3B€8.0B
Equity€2.5B€2.7B€4.0B€4.1B

What they do

In the company's own words, from the annual report.

Sartorius Stedim Biotech est un partenaire international de premier plan de l’industrie biopharmaceutique. En tant que fournisseur de solutions innovantes, le Groupe aide ses clients à fabriquer des médicaments biotechnologiques, tels que les thérapies cellulaires et géniques, de manière plus sûre, plus rapide et plus durable. Présent dans le monde entier, le Groupe possède des sites de fabrication, de R&D et de vente en Europe, en Amérique du Nord et en Asie.

Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.